In recognition of National Women's Health Week (May 14-20, 2023) Patient Care editors collected some of the most notable studies, FDA actions, and expert guidance updates from the second quarter of 2023, so far.
Topics include earlier screening for breast cancer, persistently higher post-MI adverse events in women vs men, migraine history and pregnancy complications, and more.
Find highlights of 9 top news items here and links for more information for all.
Tirzepatide Real-World Benefit Found Greater for CV, Renal Outcomes vs GLP-1 RAs in Adults with T2D
August 12th 2024In a head-to-head real world study, tirzepatide compared with semaglutide resulted in 42%, 20%, and 46% reduced risks for all-cause mortality and major adverse CV and renal events, respectively.
Primary Viewpoints Episode 7: Antidepressants for Back Pain, Osteoarthritis Pain
February 25th 2021Listen to our newest podcast episode where the lead author of a recent meta-analysis shares his findings on the safety and efficacy of antidepressant medications to treat back and osteoarthritis pain.